

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Austar Lifesciences Limited
奧星生命科技有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6118)

VOLUNTARY ANNOUNCEMENT -
ACQUISITION OF MINORITY SHAREHOLDING INTERESTS
IN NOOZLE FLUID TECHNOLOGY (SHANGHAI) CO., LTD.

This announcement is made by Austar Lifesciences Limited (“**Company**”) and together with its subsidiaries, the “**Group**” or “**AUSTAR**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest information in relation to the business development of the Company.

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of the Company is pleased to announce that the Group has completed the acquisition (“**Acquisition**”) of the minority shareholding interests in 諾澤流體科技（上海）有限公司 (Noozle Fluid Technology (Shanghai) Co., Ltd.*) (“**SHNZ**”) by way of both the acquisition of shareholding interests from an existing shareholder of SHNZ and capital injection.

SHNZ, a company established in the People’s Republic of China with limited liability in 2012, can provide complete superb solutions for the preparation in nanomedicine, inhalation and is principally engaged in the research and development, fabricating and selling of nanometre processing equipment, micron processing equipment, liposome extruder and matching systems, as well as related technologies for sectors of medicine, chemical engineering, electronics and food. SHNZ has installed a laboratory including all types of machine, ready for trialling and training.

The Acquisition will bring win-win benefit for both parties. AUSTAR, as a technology-based pharmaceutical engineering solution provider, will integrate SHNZ’s core process technology products and enhance the competence in high-end liquid preparation projects including nanometre liposomes, emulsion, suspension and high-end chemical drugs, especially inhalation preparations, anti-cancer, high-potent, sterile and other active pharmaceutical ingredient (API) solutions. By utilising AUSTAR's domestic and foreign sales channels, project execution,

manufacturing and management platforms, SHNZ will further expand the market share of its core products such as microfluidic homogenizer and jet mill widely applied in high-end nanometre targeted preparations and API solution.

The Acquisition does not constitute a notifiable transaction or a connected transaction of the Company under Chapter 14 or Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited respectively.

On behalf of the Board
Austar Lifesciences Limited
Ho Kwok Keung, Mars
Chairman and Chief Executive Officer

Hong Kong, 8 August 2022

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yuewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.

** For identification purpose only*